Marshall Wace, LLP Karyopharm Therapeutics Inc. Call Options Transaction History
Marshall Wace, LLP
- $77.3 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding KPTI
# of Institutions
98Shares Held
57.6MCall Options Held
258KPut Options Held
81.2K-
Vanguard Group Inc Valley Forge, PA7.65MShares$6.2 Million0.0% of portfolio
-
Eversept Partners, LP New York, NY5.55MShares$4.49 Million0.36% of portfolio
-
Palo Alto Investors LP Palo Alto, CA5.1MShares$4.13 Million0.58% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA4.32MShares$3.5 Million0.01% of portfolio
-
Black Rock Inc. New York, NY4.17MShares$3.38 Million0.0% of portfolio
About Karyopharm Therapeutics Inc.
- Ticker KPTI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 79,806,600
- Market Cap $64.6M
- Description
- Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and in...